Trump repeats 'MAGA Math' claim that drug costs could drop by 1,000%

Former President Donald Trump revived his signature campaign slogan on Thursday, asserting that he would force pharmaceutical companies to slash drug prices for Americans. In an appearance on Fox News, he claimed that drug costs would fall over the next year by 1,000%, insisting the reduction would exceed traditional targets such as 50% or 60%.

Trump argued that the goal could be achieved through measures aimed at reshaping how drugs are priced and reimbursed in the United States, a premise he has floated in past campaigns without releasing a full policy plan to detail how such a drastic reduction would be financed or implemented. He has repeatedly cited sweeping percentage-based promises as he speaks to supporters and critics alike, often framing them in a high-stakes, world-vs.-U.S. context.

In the broadcast clip, Trump offered a provocative hypothetical to illustrate his point about global competition and pricing dynamics: “If you think of a $10 pill -- it will be raised up from 10 to 20 because it's the world versus us, the world is the bigger place.. so it will go from 10 to 20.” The juxtaposition of a 1,000% reduction with an example that appears to raise prices underscored the rhetorical unpredictability that has followed his statements about drug costs. Critics on social media quickly mocked the claim, noting the math does not align with standard economics and suggesting the assertion would amount to paying people to take their medications under a literal interpretation.

Trump has previously floated even larger numbers, at times asserting costs would fall by 1,400% or 1,500%. Those remarks have become a fixture of his broader messaging about health care costs, even as independent analysts and policymakers point to the complexity of drug pricing, including patents, rebates, and payer negotiations.

Health policy experts say that truly slashing drug prices by orders of magnitude would require a combination of policy reforms, competition, and price controls that have not been paired with any detailed,Outside-the-campaign plan released by Trump’s team. Critics caution that dramatic claims without clear mechanisms can mislead voters and distort the policy debate at a moment when prescription drug costs are a focal point in U.S. politics.

The remarks arrive as the political environment remains highly charged ahead of competitive elections, with supporters embracing aggressive cost-cutting rhetoric and opponents urging careful consideration of feasibility and potential unintended consequences. While campaign rhetoric can shape perceptions, officials and analysts emphasize that any real-world changes would hinge on complex legislative and regulatory processes, not simple promises of percentage reductions.